A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma

This study has been completed.

Sponsor:

ClinicalTrials.gov Identifier:

NCT00722566

First Posted: July 25, 2008

Last Update Posted: October 10, 2011

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

Collaborator:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Information provided by (Responsible Party):

Millennium Pharmaceuticals, Inc.

Results First Submitted: August 30, 2011

Study Type:	Interventional
Study Design:	Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment
Condition:	Multiple Myeloma
Interventions:	Drug: VELCADE Administered by subcutaneous injection Drug: VELCADE Administered by intravenous infusion

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
VELCADE Subcutaneous	VELCADE 1.3 mg/m^2 administered by subcutaneous injection on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles.
VELCADE Intravenous	VELCADE 1.3 mg/m^2 administered by intravenous infusion on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles.

Participant Flow: Overall Study

	VELCADE Subcutaneous	VELCADE Intravenous
STARTED	148 ^[1]	74
COMPLETED	81 ^[2]	39 ^[2]
NOT COMPLETED	67	35

^[1]	One patient randomized and not dosed
^[2]	Completed 8 cycles

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
VELCADE Subcutaneous	VELCADE 1.3 mg/m^2 administered by subcutaneous injection on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles.
VELCADE Intravenous	VELCADE 1.3 mg/m^2 administered by intravenous infusion on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles.
Total	Total of all reporting groups

Baseline Measures

	VELCADE Subcutaneous	VELCADE Intravenous	Total
Overall Participants Analyzed [Units: Participants]	148	74	222

Age [Units: Participants]
<=18 years	0	0	0
Between 18 and 65 years	74	37	111
>=65 years	74	37	111

Age [Units: Years] Mean (Standard Deviation)	64.3 (8.96)	64.0 (12.11)	64.2 (10.09)

Gender [Units: Participants]
Female	74	27	101
Male	74	47	121

Region of Enrollment [Units: Participants]
France	22	14	36
Belgium	7	5	12
Germany	2	4	6
Netherlands	6	4	10
United Kingdom	6	3	9
Ukraine	51	17	68
Russian Federation	26	9	35
Poland	20	7	27
Argentina	5	8	13
India	3	3	6

Outcome Measures

Show All Outcome Measures

1. Primary:

Number of Patients With Overall Response (Complete Response + Partial Response) [ Time Frame: Over 4 cycles (prior to the addition of dexamethasone) ]

Show Outcome Measure 1

2. Secondary:

Number of Patients With Complete Response [ Time Frame: Over 4 cycles (prior to the addition of dexamethasone) ]

Show Outcome Measure 2

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:

Name/Title: Helgi Van de Velde, M.D., Ph.D.
Organization: Johnson & Johnson Pharmaceutical Research & Development
e-mail: HVDVELDE@ITS.JNJ.COM

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Rekhtman G, Masliak Z, Robak P, Esseltine DL, Feng H, Deraedt W, van de Velde H, Arnulf B. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study. Haematologica. 2015 May;100(5):e207-10. doi: 10.3324/haematol.2014.118182. Epub 2015 Jan 16.

Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011 May;12(5):431-40. doi: 10.1016/S1470-2045(11)70081-X. Epub 2011 Apr 18. Erratum in: Lancet Oncol. 2011 Jun;12(6):522.

Responsible Party:	Millennium Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:	NCT00722566 History of Changes
Other Study ID Numbers:	26866138 MMY 3021
First Submitted:	July 23, 2008
First Posted:	July 25, 2008
Results First Submitted:	August 30, 2011
Results First Posted:	October 4, 2011
Last Update Posted:	October 10, 2011

To Top